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Abstract
High blood pressure is an important constituent of the metabolic syndrome. However, the
underlying mechanisms for development of hypertension in the metabolic syndrome are very
complicated and remain still obscure. Visceral/central obesity, insulin resistance, sympathetic
overactivity, oxidative stress, endothelial dysfunction, activated renin-angiotensin system, increased
inflammatory mediators, and obstructive sleep apnea have been suggested to be possible factors to
develop hypertension in the metabolic syndrome. Here, we will discuss how these factors influence
on development of hypertension in the metabolic syndrome.
Introduction
The metabolic syndrome is characterized by the simulta-
neous occurrence of metabolic abnormalities including
obesity, glucose intolerance, dyslipidemia, and hyperten-
sion, that result in a marked increase in cardiovascular
morbidity and mortality [1-3]. High blood pressure is a
classical feature of the metabolic syndrome, and it has
been reported that the metabolic syndrome is present in
up to one third of hypertensive patients [4,5]. Therefore,
high blood pressure is included in the definition for the
metabolic syndrome that presented by the World Health
Organization, the National Cholesterol Education Pro-
gram, the International Diabetes Federation, and the
American Heart Association/National Heart, Lung, and
Blood Institutes [1-3,6]. Blood pressure levels are strongly
associated with visceral obesity and insulin resistance [7],
which are the main pathophysiologic features underlying
the metabolic syndrome. Here, we will discuss the under-
lying mechanisms for development of hypertension in the
metabolic syndrome.
The underlying mechanisms for development of 
hypertension in the metabolic syndrome
Proposed mechanisms for development of hypertension
in the metabolic syndrome were shown in Figure 1.
Visceral obesity
Excess food intake and physical inactivity underlie the
growing worldwide epidemic of obesity. Hyperglycemia,
hyperlipidemia, and hypertension are common in obese
individuals [8,9]. Visceral obesity has been suggested to
play a fundamental role in the simultaneous development
of these disorders [10]. Recent studies have demonstrated
that adipose tissue is a major endocrine organ that secrets
a variety of bioactive substances, termed adipocytokines.
Adipocytokines secretion are altered as obesity develops,
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which may induce the metabolic disorders. As shown in
Figure 1, accumulated visceral adipose tissue produce and
secrete a number of adipocytokines, such as leptin, tumor
necrosis factor-α (TNF-α), interleukin-6 (IL-6), angi-
otensinogen, and non-esterified fatty acids (NEFA), which
induce development of hypertension [11]. Visceral obes-
ity is the main cause of the metabolic syndrome, and is
associated with development of hypertension in the met-
abolic syndrome via a variety of pathways (Figure 1).
Insulin resistance
Insulin resistance is the main pathophysiologic feature of
the metabolic syndrome. Several mechanisms connect
insulin resistance with hypertension in the metabolic syn-
drome. An anti-natriuretic effect of insulin has been estab-
lished by accumulating data indicating that insulin
stimulates renal sodium re-absorption [12-14]. This anti-
natriuretic effect is preserved, and may be increased in
individuals with insulin resistance, and this effect may
play an important role for development of hypertension
in the metabolic syndrome [15]. Strazzullo P, et al. inves-
tigated the relationship between the metabolic syndrome
and renal tubular sodium handling [16]. In their study,
proximal fractional sodium re-absorption (FPRNa) was
significantly greater in individuals with the metabolic syn-
drome, as compared with those without the metabolic
syndrome [16]. Further, in untreated obese individuals,
age-adjusted FPRNa was significantly greater in individu-
als with insulin resistance as compared with those with-
out insulin resistance [16]. Insulin resistance is also
associated with development of salt-sensitive hyperten-
sion through the anti-natriuretic effect of insulin [17].
In vitro studies have shown that insulin stimulates both
endothelin-1 production and its action on the vascular
wall [18]. In vivo study has also demonstrated that high
serum insulin level is associated with an increase in circu-
lating endothelin-1 in healthy and insulin-resistant indi-
viduals [18]. Endothelin-1 receptor antagonism
effectively reduced blood pressure in animal models of
insulin resistance and hypertension [18], suggesting a sig-
Proposed mechanisms for development of hypertension in the metabolic syndrome Figure 1
Proposed mechanisms for development of hypertension in the metabolic syndrome. IL-6, interleukin-6; NEFA, 
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nificance of endothelin-1 in the pathogenesis of hyperten-
sion in insulin resistance.
Sympathetic overactivity
Serum catecholamine concentrations and muscle sympa-
thetic nervous activity (MSNA) were significantly
increased in obese individuals as compared with lean
individuals [19], and MSNA in subjects with central obes-
ity were significantly greater than those in individuals
with peripheral obesity [19]. Elevated resting heat rates
[20,21], and baroreflex dysfunction have been reported to
play an important role in development of hypertension in
the metabolic syndrome [22]. Individuals with obstruc-
tive sleep apnea (OSA) have a high prevalence of the met-
abolic syndrome [23,24], and OSA has been reported to
be associated with sympathetic overactivity. Obese indi-
viduals exhibit an activated renin-angiotensin system
[25], which induces hypertension. The renin-angiotensin
system and sympathetic nervous system are linked by a
positive feedback relationship [26]. Insulin resistance,
increased leptin and NEFA levels have been indicated to
be possible factors augmenting sympathetic nervous acti-
vation in the metabolic syndrome [27]. NEFA has been
reported to raise blood pressure, heart rate, and α1-adren-
oceptor vasoreactivity, while reducing baroreflex sensitiv-
ity, endothelium-dependent vasodilatation, and vascular
compliance [28]. Insulin resistance increases plasma lep-
tin levels, and leptin has been reported to elevate sympa-
thetic nervous activity, suggesting that leptin-dependent
sympathetic nervous activation may contribute to an
obesity-associated hypertension [29]. Accumulating data
suggest that metabolic syndrome is associated with mark-
ers of adrenergic overdrive [30].
Oxidative stress and endothelial dysfunction
In rats with the metabolic syndrome, induced by chronic
consumption of a high fat, high refined sugar [31], hyper-
tension is associated with oxidative stress [32], avid nitric
oxide (NO) inactivation, and down-regulation of NO syn-
thase (NOS) isoforms and endothelial NOS activator
[32], suggesting that oxidative stress and endothelial dys-
function may be strongly associated with development of
hypertension in the metabolic syndrome. Further, recent
evidences suggest that oxidative stress, which is elevated
in the metabolic syndrome [33], is associated with
sodium retention and salt sensitivity [34].
In non-diabetic human subjects, lipid peroxidation, rep-
resented by plasma thiobarbituric acid reactive substance
and urinary 8-epi-prostaglandin-F2α, were significantly
and positively correlated with body mass index and waist
circumference, indicating that fat accumulation is corre-
lated with oxidative stress in humans [33]. Cross-sectional
data from 2,002 non-diabetic subjects of the community-
based Framingham Offspring Study has shown that sys-
temic oxidative stress is associated with insulin resistance
[35]. Insulin resistance induces an impairment in phos-
phatidylinositol 3-kinase (PI3K) – dependent signaling,
which in endothelium may cause imbalance between pro-
duction of nitric oxide and secretion of endothelin-1,
leading to endothelial dysfunction [36]. Epidemiological
studies strongly support a reciprocal relationship between
endothelial dysfunction, which contributes to develop-
ment of hypertension, and insulin resistance [36]. In a
prospective cohort study, each one-unit decrease of flow-
mediated dilatation was associated with a significant 16%
(95% confidence interval: 12–33%) increase in the multi-
ple-adjusted relative risk of incident hypertension, sug-
gesting that an impaired endothelial vasomotor function
precedes and predicts the future development of hyper-
tension [37].
Activated renin-angiotensin system
The renin-angiotensin system (RAS) plays a crucial role in
blood pressure regulation, by affecting renal function and
by modulating vascular tone. The activity of the RAS
appears to be regulated by food intake, and overfeeding of
rodents has been reported to lead to increased formation
of angiotensin II in adipocytes [38]. Angiotensinogen,
angiotensin converting enzyme, and type 1 angiotensin
receptor gene are widely expressed in human adipose tis-
sue [39], and production of angiotensin II and angi-
otensinogen in adipose tissue may be increased in obese
subjects. Goodfriend TL, et al. measured plasma aldoster-
one levels in adults with various values of body mass
index [40]. Plasma aldosterone level was higher in obese
subjects, but could not be explained by renin and potas-
sium [40]. The best predictor for plasma aldosterone level
was abdominal obesity [40]. Elevated renin and aldoster-
one levels have been observed in subjects with multiple
risk factors as compared with those without multiple risk
factors [41]. Plasma aldosterone has been reported to be
significantly associated with the metabolic syndrome and
also with obesity-related hypertension [42,43].
There are accumulating data indicating that angiotensin II
inhibits the action of insulin via angiotensin type 1 recep-
tor, in vascular muscle tissue, by interfering with insulin
signaling through PI3K and its downstream protein
kinase B (Akt) signaling pathway [44]. This inhibitory
action of angiotensin II is mediated through stimulation
of RhoA activity and oxidative stress [44]. Increased RhoA
activity and reactive oxygen species inhibit PI3K/Akt sign-
aling, resulting in decreased NO production in endothe-
lial cell and increased vasoconstriction [44]. Activated
RAS may contribute to development of hypertension in
the metabolic syndrome.Nutrition Journal 2008, 7:10 http://www.nutritionj.com/content/7/1/10
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Increased inflammatory mediators
Recent cohort studies have demonstrated that high-sensi-
tivity C-reactive protein (hsCRP) independently presents
additive prognostic values at all levels of metabolic syn-
drome [45]. Ridker PM, et al. suggest a consideration of
adding hsCRP as a clinical criterion for metabolic syn-
drome [45]. Abnormalities in inflammatory mediators
have been also reported to be implicated with develop-
ment of hypertension. A positive relationship between
increased serum levels of CRP and the risk for develop-
ment of incident hypertension in participants of the
Women's Health Study [46]. Grundy SM suggests a signif-
icant association among inflammation, hypertension,
and the metabolic syndrome [47].
TNF-α is involved in the pathophysiology of hypertension
in the metabolic syndrome. TNF-α stimulates the produc-
tion of endothelin-1 and angiotensinogen [48,49]. The
TNF-α gene locus seems to be involved in human insulin
resistance-mediated hypertension [50]. Serum TNF-α con-
centration has been reported to be positively correlated
with systolic blood pressure and insulin resistance in
humans [51], and increased TNF-α secretion has been
observed in monocytes from hypertensive patients [52].
IL-6 is a multifunctional cytokine which mediates inflam-
matory responses. Recent study demonstrated that blood
pressure was a significant and independent predictor of
serum IL-6 concentrations in women [53]. IL-6 stimulates
the central nervous system and sympathetic nervous sys-
tem, which may result in hypertension [54,55]. The
administration of IL-6 leads to elevation in heart rate and
serum norepinephrine levels in women [56]. Further, IL-6
induces an increase in plasma angiotensinogen and angi-
otensin II [57], leading to development of hypertension.
Obstructive sleep apnea
Of 146 patients with OSA, 88 (60%) had the metabolic
syndrome, whereas 33 of 82 patients (40%) without OSA
had the metabolic syndrome, suggesting high prevalence
of the metabolic syndrome in OSA patients [58]. The pro-
portion with hypertension was significantly higher in the
OSA group (77%) than in the non-OSA group (51%),
indicating a significant association between OSA and
hypertension [58]. Kono M et al. also demonstrated that
the percentage of hypertensive patients were significantly
higher in the OSA group (45%) than in the non-OSA
group (15%) [59]. There are accumulating evidences sug-
gesting a significant association between the metabolic
syndrome and OSA or its components [60]. Patients with
OSA are often considered to be obese, however, Kono M
et al. reported that OSA was associated with hypertension,
dyslipidemia, and hyperglycemia, independent of visceral
obesity [59]. Recent epidemiological and clinical data sug-
gest a crucial role of OSA in development of hypertension,
however, associations of OSA with insulin resistance and
dyslipidemia are controversial [60]. Visceral obesity
remains a confounding issue in studying the association
between OSA and the metabolic syndrome.
OSA is characterized by an increased number of sympa-
thetic bursts, a raised plasma norepinephrine concentra-
tion, and a reduction in baroreflex sensitivity [23,24,61],
which leaves no doubt as to the existence of sympathetic
activation induced by baroreflex dysfunction, much like
what has been observed in the metabolic syndrome. In
OSA, the nocturnal episodes of hypoxia and hypercapnia
induce the stimulation of arterial chemoreceptors, which
could induce sympathostimulating effects [61]. Hyperlep-
tinemia, insulin resistance, elevated angiotensin II and
aldosterone levels, oxidative stress, inflammation, and
endothelial dysfunction have been also suggested to be
possible mechanisms whereby OSA may contribute to
development of hypertension [62].
Conclusion
Visceral obesity, insulin resistance, oxidative stress,
endothelial dysfunction, activated renin-angiotensin sys-
tem, increased inflammatory mediators, and obstructive
sleep apnea have been proposed to be possible factors to
develop hypertension in the metabolic syndrome. These
factors may induce sympathetic overactivity, vasoconstric-
tion, increased intravascular fluid, and decreased vasodil-
atation, leading to development of hypertension in the
metabolic syndrome.
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